Edition:
United Kingdom

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

6.21USD
19 Sep 2018
Change (% chg)

$0.09 (+1.47%)
Prev Close
$6.12
Open
$6.16
Day's High
$6.30
Day's Low
$6.16
Volume
234,407
Avg. Vol
646,487
52-wk High
$7.66
52-wk Low
$4.34

Chart for

About

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $1,082.14
Shares Outstanding(Mil.): 216.43
Dividend: --
Yield (%): --

Financials

  TXMD.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -0.45 -- --
ROI: -68.00 15.07 14.61
ROE: -68.00 16.59 16.33

TherapeuticsMD's therapy for menopause-related condition gets approval

Women's healthcare company TherapeuticsMD Inc won its first-ever U.S. approval on Wednesday with the drug regulator clearing its hormone therapy for a painful condition triggered by menopause after rejecting it a year earlier.

30 May 2018

UPDATE 2-TherapeuticsMD's therapy for menopause-related condition gets approval

* Shares volatile; last down 2 pct (Adds analyst, CEO comment, share movement)

30 May 2018

FDA approves TherapeuticsMD's hormone therapy

May 30 The U.S. Food and Drug Administration approved TherapeuticsMD Inc's hormone therapy for a painful condition triggered by menopause, the women's health company said on Wednesday.

30 May 2018

BRIEF-Therapeutics MD Reports Loss Per Share Of $0.11

* THERAPEUTICSMD ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

03 May 2018

BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR

* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR

11 Apr 2018

Earnings vs. Estimates